Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Pirtobrutinib in CLL: Current and Potential Utility in the Treatment…

Nicole Lamanna

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillatio…

Avirup Guha

Guidelines for Dose Reduction of Ibrutinib in CLL

Matthew McKinney

ASCO® 2024 Insights: "CAPTIVATE Study - 5.5-Year Follow-Up Outcomes …

2024 ASCO® Annual Meeting Insights Hub

R. Jacobs

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

Constantine Tam

Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrilla…

Lydia Scarfò

Current Options for Finite-Duration Therapy With BTKis in CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

Case Discussion: Managing Anemia in a Patient With CLL & Metastatic …

Cleveland Clinic Taussig Cancer Institute

B. Estfan, K. McCrae, P. Caimi

State-of-the-Art in CLL Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Cuneo